

Piramal Healthcare invest USD\$ 2.5 millions

29 July 2013 | News | By BioSpectrum Bureau

Piramal Healthcare invest USD\$ 2.5 millions



Piramal's Healthcare vertical declared that it is going to invest whopping amount of USD 2.5 millions at its FDA approved Grangemouth, UK site to ascent one of its ADC manufacturing suites, from clinical to commercial phase owing to great customer demand.

Vijay Shah, Executive Director & Chief Operating Officer of Piramal enterprises, says, "This investment supporting an emerging platform in the field of oncology treatment, aligns completely with our values as an organization. We view ADC's as a strategic area of growth for our Pharma Solutions business and this investment indicates our determination to support our customers with facility and capacity."

The batch size offered from the Grangemouth facility ranges from 1-1.5 kg. However they have capacity for further expansion on site if required. As a part of the investment, the areas supporting the manufacturing suite will also be upgraded to new areas for buffer preparation, equipment preparation and antibody freeze/thaw. They also intend to expand its 'Proof of Concept' (POC) offer at Grangemouth, for pharma companies looking to demonstrate antibody and toxin suitability for use as an ADC.